强生(JNJ.US)以每股132美元现金收购Intra-Cellular(ITCI.US) 扩大精神疾病药物组合

智通财经01-13

智通财经APP获悉，强生(JNJ.US)已同意以每股132.00美元的现金收购生物制药公司Intra-Cellular Therapies(ITCI.US)的所有流通股，总股权价值约为146亿美元。受此消息提振，截至发稿，Intra-Cellular Therapies周一美股盘前暴涨近36%。这笔交易预计将于今年晚些时候完成，但需获得相关监管部门、Intra-Cellular Therapies...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2503305182?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-13 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503305182","market":"us","top_or_hot":-1,"title":"强生(JNJ.US)以每股132美元现金收购Intra-Cellular(ITCI.US) 扩大精神疾病药物组合","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，强生(JNJ.US)已同意以每股132.00美元的现金收购生物制药公司Intra-Cellular Therapies(ITCI.US)的所有流通股，总股权价值约为146亿美元。受此消息提振，截至发稿，Intra-Cellular Therapies周一美股盘前暴涨近36%。这笔交易预计将于今年晚些时候完成，但需获得相关监管部门、Intra-Cellular Therapies...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1237022.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生(JNJ.US)以每股132美元现金收购Intra-Cellular(ITCI.US) 扩大精神疾病药物组合</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生(JNJ.US)以每股132美元现金收购Intra-Cellular(ITCI.US) 扩大精神疾病药物组合\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 20:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1237022.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，强生(JNJ.US)已同意以每股132.00美元的现金收购生物制药公司Intra-Cellular Therapies(ITCI.US)的所有流通股，总股权价值约为146亿美元。受此消息提振，截至发稿，Intra-Cellular Therapies周一美股盘前暴涨近36%。这笔交易预计将于今年晚些时候完成，但需获得相关监管部门、Intra-Cellular Therapies...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1237022.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002224.SGD","symbol_name":"Allianz Global High Payout SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1237022.html","article_id":"2503305182","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503305182","pubTimestamp":1736771422,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，强生已同意以每股132.00美元的现金收购生物制药公司Intra-Cellular Therapies的所有流通股，总股权价值约为146亿美元。受此消息提振，截至发稿，Intra-Cellular Therapies周一美股盘前暴涨近36%。这笔交易预计将于今年晚些时候完成，但需获得相关监管部门、Intra-Cellular Therapies股东的批准以及其他常规成交条件。这笔交易加强了强生的神经系统疾病产品组合。资料显示，Intra-Cellular Therapies专注于开发和商业化中枢神经系统疾病治疗方法。此外，Intra-Cellular Therapies开发的Lumateperone是一种口服非典型抗精神病药物。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999002224.SGD":"Allianz Global High Payout SGD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4532":"文艺复兴科技持仓","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","ITCI":"Intra-Cellular Therapies Inc.","BK4581":"高盛持仓","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4534":"瑞士信贷持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4533":"AQR资本管理(全球第二大对冲基金)","JNJ":"强生","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4504":"桥水持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4559":"巴菲特持仓","BK4592":"伊斯兰概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4550":"红杉资本持仓","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)"},"translate_title":"Johnson & Johnson (JNJ.US) buys Intra-Cellular (ITCI.US) for $132 per share in cash to expand mental illness drug portfolio","themeId":"f4cb143b077bc1abedb185974e2d66a5","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITCI":1,"JNJ":1},"content_text":"智通财经APP获悉，强生(JNJ.US)已同意以每股132.00美元的现金收购生物制药公司Intra-Cellular Therapies(ITCI.US)的所有流通股，总股权价值约为146亿美元。受此消息提振，截至发稿，Intra-Cellular Therapies周一美股盘前暴涨近36%。这笔交易预计将于今年晚些时候完成，但需获得相关监管部门、Intra-Cellular Therapies股东的批准以及其他常规成交条件。此次交易将通过现金和债务相结合的方式筹资。这笔交易加强了强生的神经系统疾病产品组合。资料显示，Intra-Cellular Therapies专注于开发和商业化中枢神经系统疾病治疗方法。该公司目前正在研发一种治疗重度抑郁症的药物，该药物正处于后期试验阶段。此外，Intra-Cellular Therapies开发的Lumateperone是一种口服非典型抗精神病药物。Lumateperone于2019年获美国食品药品管理局(FDA)批准用于治疗精神分裂症，并于2021年12月获得了与双相情感障碍相关的抑郁症发作的适应症扩展。强生将于2025年1月22日举行的第四季度财报电话会议上公布该交易对调整后每股收益的潜在影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2503305182","isCrawlerRequest":true}